Daniel Behroozan, MD
Dermatology · Santa Monica, CANPI 1851325716
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $113,193 of the $138,798 with a category attached, or 81.6%. Galderma Laboratories, L.p. accounts for 69.1% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2023 at $40,860 and has fallen 75.9% since, to $9,857 in 2025. Among dermatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 730 payments — averaging $190.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$96K
- Pfizer$23K
- AbbVie$10K
- Biofrontera Inc.$2K
- Amgen$1K
- Incyte Corporation$755
- plus $6K from 36 others
What the payments were for
- Consulting fees$1,5001%
- Speaking & faculty fees$113,19382%
- Travel & lodging$4,0133%
- Food & beverage$19,86014%
- Education$2320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AKLIEF$77,825
- TWYNEO$37,248
- ORACEA$24,515
- EPSOLAY$24,024
- EPIDUO FORTE$11,825
- EUCRISA$8,192
- CIBINQO$6,500
- AMELUZ$1,500
- BF-RhodoLED$1,500
- XEPI$1,500
- BOTOX$840
- VTAMA$358
- Klisyri$261
- Otezla$242
- OPZELURA$228
- Sitavig$209
- Cloderm$209
- Minolira 105mg$209
- Minolira 135mg$209
- Rhofade$209
How this compares
$138,798 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 16 | $796 |
| Cephalexin | 94 | $402 |
| Ketoconazole | 18 | $235 |
| Mupirocin | 23 | $195 |
| Doxycycline Hyclate | 15 | $111 |
| Azithromycin | 14 | $91 |
| Triamcinolone Acetonide | 11 | $38 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Santa Monica
- Paul YamauchiSanta Monica$2.9M
- Ava ShambanSanta Monica$204K
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
- Tien NguyenFountain Valley$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.